Seattle Genetics

(NASDAQ: SGEN)
Healthcare  |  Biotechnology
181.17 0.0 0.0%
Stock Price | July 9, 2020, 4 p.m.
0 Followers
Bid: 0.0
Ask: 0.0
Prev. Close: 181.17
52 Week Low: 63.02
52 Week High: 182.97
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Seattle Genetics is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Read more Read less

Recently Viewed Tickers

Free Stock Watchlist 09/07/2016

3 years ago